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A B S T R A C T
The human host comprises a range of specific niche environments. In order to successfully persist, pathogens
such as Aspergillus fumigatus must adapt to these environments. One key example of in-host adaptation is the
development of resistance to azole antifungals. Azole resistance in A. fumigatus is increasingly reported world-
wide and the most commonly reported mechanisms are cyp51A mediated. Using a unique series of A. fumigatus
isolates, obtained from a patient suffering from persistent and recurrent invasive aspergillosis over 2 years, this
study aimed to gain insight into the genetic basis of in-host adaptation. Single nucleotide polymorphisms (SNPs)
unique to a single isolate in this series, which had developed multi-azole resistance in-host, were identified. Two
nonsense SNPs were recreated using CRISPR-Cas9; these were 213* in svf1 and 167* in uncharacterised gene
AFUA_7G01960. Phenotypic analyses including antifungal susceptibility testing, mycelial growth rate assess-
ment, lipidomics analysis and statin susceptibility testing were performed to associate genotypes to phenotypes.
This revealed a role for svf1 in A. fumigatus oxidative stress sensitivity. In contrast, recapitulation of 167* in
AFUA_7G01960 resulted in increased itraconazole resistance. Comprehensive lipidomics analysis revealed de-
creased ergosterol levels in strains containing this SNP, providing insight to the observed itraconazole resistance.
Decreases in ergosterol levels were reflected in increased resistance to lovastatin and nystatin. Importantly, this
study has identified a SNP in an uncharacterised gene playing a role in azole resistance via a non-cyp51A
mediated resistance mechanism. This mechanism is of clinical importance, as this SNP was identified in a clinical
isolate, which acquired azole resistance in-host.
1. Introduction
In order to survive in-host, the human fungal pathogen Aspergillus
fumigatus must adapt to specific niche environments (Verweij et al.,
2016). Adaptation can occur as a result of spontaneous mutation and
subsequent selection. One clinically important example of in-host
adaptation is the development of resistance to azole antifungals. Azole
resistance in A. fumigatus is being increasingly reported globally
(Denning and Perlin, 2011). A range of mutations in the cyp51A gene,
which encodes the ergosterol biosynthetic enzyme lanosterol 14-alpha-
demethylase, have been shown to cause azole resistance by altering the
structure of ligand access channels. Amino acid changes in these
channels are thought to disturb docking of azole molecules by altering
interactions (Snelders et al., 2010). These include mutations such as
P216, G138, M220 and G54 (Albarrag et al., 2011; Garcia-Effron et al.,
2005; Mann et al., 2003; Mellado et al., 2004; Snelders et al., 2010). In
addition, tandem repeats in the promoter region of cyp51A, in combi-
nation with L98H within the cyp51A coding region, have been shown to
confer itraconazole resistance (Gsaller et al., 2016; Mellado et al., 2007;
Snelders et al., 2008; Zhang et al., 2017). Few non-cyp51A mediated
resistance mechanisms have been described in A. fumigatus thus far.
One example is P88L in the HapE subunit of the CCAAT-binding com-
plex, which is a multimeric transcription factor acting as a negative
regulator of ergosterol biosynthesis (Camps et al., 2012; Gsaller et al.,
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2016). Other proteins reported to be associated with azole resistance
include RamA (farnesyltransferase β-subunit), mitochondrial complex I
and efflux transporters AtrF and Cdr1B (Bromley et al., 2016; Fraczek
et al., 2013; Norton et al., 2017; Slaven et al., 2002).
We have previously shown that A. fumigatus undergoes significant
in-host adaptation using a large series of isogenic strains, isolated from
a single patient over a two year period (Ballard et al., 2018; Verweij
et al., 2016). Phenotypic analyses revealed that these isogenic strains
developed in-host azole antifungal resistance, changes in colony mor-
phology, defects in conidiation, and alterations in virulence (Ballard
et al., 2018). Whole genome comparisons identified 248 non-synon-
ymous single nucleotide polymorphisms (SNPs) that were absent in the
early isolates but present in strains subsequently isolated from the pa-
tient. We hypothesise that these SNPs could potentially play a role in
the observed in-host adaptation and possibly enable persistent infection
(Ballard et al., 2018). Here we extend our previous study by in-
vestigating the phenotypic impact of selected SNPs using a newly de-
veloped CRISPR-Cas9 method to recapitulate specific SNPs observed in
clinical A. fumigatus strains.
In this study, we focused on one particular strain of interest from
our series of 13 isogenic strains. This strain, V157-62, was multi-azole
resistant (MIC itraconazole > 16mg/L, voriconazole 8mg/L and po-
saconazole > 16mg/L), harboured M220R in cyp51A which partially
explained its resistance profile (Chen et al., 2005; Garcia-Effron et al.,
2005; Mellado et al., 2004) and also showed a severe growth defect
(Ballard et al., 2018). Unique to this strain were 14 non-synonymous
SNPs in 8 genes: 12 of these were missense variants, of which the im-
pact on the encoded protein is unclear. However, 2 SNPs generated
premature stop codons, which could result in loss, or at least pertur-
bation, of protein function. One SNP was 213* identified in svf1, which
is known to play a role in oxidative stress responses in Saccharomyces
cerevisiae (Brace et al., 2005). The second SNP was 167* identified in an
uncharacterised gene (AFUA_7G01960). These 2 nonsense mutations
were selected for further investigation using CRISPR-Cas9 and were
recreated in the first isolate of the series (V130-15). Our phenotypic
analyses showed that one SNP influenced oxidative stress sensitivity.
Interestingly, we also showed the role of an in-host acquired SNP in an
uncharacterised gene resulting in increased azole resistance. Using
comprehensive lipidomics analysis this SNP was associated with de-
creased ergosterol levels. These data provide evidence for a novel in-
host acquired non-cyp51-mediated azole resistance mechanism in A.
fumigatus.
2. Materials and methods
2.1. Origin of fungal isolates
We focused on A. fumigatus strain V157-62, which is one of the
isolates from a series of 13 strains isolated from a patient diagnosed
with X-linked chronic granulomatous disease who suffered from
recurrent/persistent aspergillosis over a period of 2 years (Ballard et al.,
2018; Verweij et al., 2016). In addition, two isolates from the same
patient V130-15 (azole-susceptible phenotype) and V157-39 (azole-re-
sistant phenotype with G54R mutation in cyp51A) were used for mo-
lecular experimentation. All strains have previously been phenotypi-
cally and genotypically characterised by us (Ballard et al., 2018).
Firstly, as a control of the CRISPR-Cas9 method, we reversed the
G54R mutation in cyp51A to WT in V157-39. Then we focused on SNPs
identified in V157-62. Whole genome comparisons previously per-
formed, identified several SNPs unique to V157-62 (Ballard et al.,
2018). Two of these SNPs were selected for further investigation as they
may result in protein truncations. These SNPs were 213* in svf1 (sur-
vival factor 1; AFUA_5G11820) and 167* in the uncharacterised gene,
AUFA_7G01960. These SNPs were recreated in the azole susceptible
strain V130-15 (the first strain isolated in the series). This approach was
selected as it enabled the phenotypes associated with each SNP to be
investigated individually in a susceptible clinical isolate, with an iso-
genic genetic background to the isolate in which the SNPs were iden-
tified, but with a wild-type growth phenotype.
Strains used in this study are shown in Table 1. Also summarised in
Table 1 are previously published isolation dates, genotypes and the
number of non-synonymous SNPs different between each isolate
(Ballard et al., 2018).
2.2. Molecular techniques
2.2.1. General molecular techniques
Plasmids were designed using Benchling (www.benchling.com). All
PCR reactions were performed using Phusion Flash High-Fidelity PCR
Master Mix (Thermo Fisher Scientific, UK) and purified using the
QIAquick® PCR purification kit (Qiagen, UK). Sanger sequencing was
performed using the Lightrun service (GATC Biotech, Germany) and
analysed using GATCViewer software. DNA was quantified using a
Nanodrop 1000 (Thermo Fisher Scientific, USA).
2.2.2. Genomic DNA extraction
Fungal strains were grown overnight in liquid glucose minimal
media at 37 °C and 200 rpm. Genomic DNA was extracted from the
mycelium using the DNeasy Plant Mini Kit (Qiagen, Germany). Mycelia
were disrupted in the presence of AP1 buffer, RNAse and glass beads
using a FastPrep-24 (MP Biomedicals, UK) at max speed for 1min. The
kit DNA extraction procedure was subsequently followed.
2.2.3. CRISPR-Cas9 preparation
We used a method adapted from previously published methods
(Nødvig et al., 2015; Weber et al., 2016). Two plasmids and donor DNA
containing the desired SNP sequence were used. Plasmid 1 encoded
AMA1, Cas9, hygromycin resistance and ampicillin resistance. The
second plasmid, which was target specific, encoded the guide RNA,
hammerhead ribozyme, protospacer, ampicillin resistance and split-
Table 1
Description of A. fumigatus isolates in the study including minimum inhibitory concentrations.
Isolation date Strain Genotype Number of non-synonymous single
nucleotide polymorphisms different
Minimum inhibitory concentration (MIC; mg/L)
Itraconazole Voriconazole Posaconazole Amphotericin B
22/11/11 V130-15 WT cyp51A 1 1 0.25 0.5
V130-15svf1213* 213* in svf1 1 1 0.25 0.5
V130-15unc167* 167* in AFUA_7G01960 4 2 0.25 0.5
9/12/13 V157-
39cyp51AG54R
G54R in cyp51A 21 different from V130-15
35 different from V157-62
>16 1 >16 0.5
V157-39cyp51AWT WT cyp51A 0.5 1 >16 0.5
9/12/13 V157-62 M220R in cyp51A; 213* in svf1;
167* in AFUA_7G01960
29 different from V130-15
35 different from V157-39
>16 8 >16 0.25
Bold indicates a MIC exceeding the EUCAST clinical resistance breakpoint; which are defined as itraconazole > 2mg/L, voriconazole > 2mg/L, posacona-
zole > 0.25mg/L and amphotericin B > 2mg/L.
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pyrithiamine resistance. Protospacer adjacent motif (PAM) and proto-
spacer sequences near to the target site were identified manually using
publicly available sequences obtained from AspGD (www.aspgd.org).
Selected PAM and protospacer sequences are shown in Fig. A.1. Plasmid
2 was created for each individual target according to the previously
published method (Nødvig et al., 2015). Using a plasmid template and
overlapping PCR primer pairs, fragments of the target specific plasmid
could be obtained. DpnI digestion was used to remove residual plasmid
template. Gibson assembly was used to ligate plasmid fragments and
was performed using the NEBuilder® HiFi DNA Assembly Master Mix
(New England Biolabs, UK). Plasmids were propagated using sub-
cloning efficiency DH5α Escherichia coli (Invitrogen, UK) grown on LB
agar with 100 µg/ml ampicillin (Sigma Aldrich, UK). Donor DNA was
produced by PCR using genomic DNA from strains containing the target
SNP. Primers used are shown in Table A.1.
2.2.4. CRISPR-Cas9 transformation
Three clinical isolates are utilised in this study. Strain V130-15 was
the initial clinical isolate and V157-39 was a subsequent isolate that
evolved azole resistance in-host. Isolate V157-62 was a later isolate
which has acquired azole resistance and a growth defect in-host; this
isolate was used to identify SNPs (see Table 1). The SNPs identified in
V157-62 were recreated in the initial isolate V130-15.
A. fumigatus cultures grown overnight in liquid glucose minimal
media at 37 °C and 200 rpm were harvested using a 40 µm strainer.
Protoplasts were made using a modification of a published protocol
(Ballance et al., 1983; Ballance and Turner, 1985). The fungal biomass
was transferred into an Erlenmeyer flask containing protoplasting so-
lution consisting of Vinotaste Pro (Novozymes, Denmark) dissolved in
Trafo I (0.6 M KCl, 10mM Na2PO3, pH 5.8). The flask was incubated at
30 °C and 80 rpm for 3 h; every 30min the solution was resuspended
using a serological pipette. Protoplast formation was monitored using a
light microscope, once formed, protoplasts were filtered using 40 µm
strainer washed with Trafo I. Protoplasts were centrifuged at 4 °C and
4000 rpm for 5min. The pellet was resolved in Trafo II (0.6M KCl,
100mM Tris, pH 7) and washing was repeated. The pellet was subse-
quently resolved in Trafo III (0.6M KCl, 10mM Tris, pH 7.5). Proto-
plasts were transformed on ice using PEG solution (25% PEG 8000 in
Trafo III), 3 µg of each plasmid and 1 µg donor DNA. Transformants
were mixed into glucose minimal agar containing 1M sorbitol, 1 µg/ml
pyrithiamine hydrobromide (Sigma Aldrich, UK) and 100 µg/ml hy-
gromycin B (Roche, UK) and incubated at 37 °C. Colonies were streak
purified with and then without selection markers. It is important to note
that without selection, plasmid 1 (which encodes AMA1 and Cas9) is
readily lost from the fungus, preventing further gene editing from oc-
curring in the strain after streak purification (Aleksenko and
Clutterbuck, 1997; Nødvig et al., 2015). Single nucleotide changes were
verified using PCR and Sanger sequencing.
2.3. Phenotypic analysis
2.3.1. Conidial suspension preparation
A. fumigatus conidia were spread onto Sabouraud dextrose agar in
T75 culture flasks (Greiner Bio-One, Germany) and incubated at 37 °C
for 7 d. Conidia were harvested via immersion in phosphate buffered
saline (PBS) (Thermo Fisher Scientific, UK) containing 0.05% Tween-80
(Thermo Fisher Scientific, UK). Conidial suspensions were filtered using
a 40 µm strainer, washed twice using PBS and counted using a
Neubauer improved haemocytometer.
2.3.2. Susceptibility testing
In vitro susceptibility testing of the isolates against antifungals and
statins was performed according to the EUCAST broth microdilution
reference method (EUCAST, 2015). Nystatin (Sigma Aldrich, UK) and
lovastatin (Sigma Aldrich, UK) were solubilized in dimethyl sulfoxide
(DMSO), diluted in double strength RPMI and tested at final
concentrations of 16 µg/ml and 256 µg/ml respectively. After incuba-
tion with statins for 48 h, an XTT (2,3-bis(2-methoxy-4-nitro-5-sulfo-
phenyl)-2H-tetrazolium-5-carboxanilide) assay was performed to
quantify fungal viability (Meletiadis et al., 2001). Susceptibility testing
was performed in duplicate with 3 technical repeats per experiment.
2.3.3. Mycelial growth rate analysis
Sabouraud dextrose agar plates were spot-inoculated with 5x102
conidia. Selected plates were supplemented with 2.5mM H2O2. Plates
were incubated at 37 °C (unless otherwise indicated) for 96 h. Colony
diameters were measured every 24 h. Each condition was performed in
duplicate with 3 technical repeats per experiment.
2.3.4. In silico analysis of uncharacterised protein
Exon only nucleotide and amino acid sequences were obtained from
AspGD (www.aspgd.org/) and UniProt (www.uniprot.org). Sequences
were used in NCBI conserved domain search and BLAST analyses
(Altschul et al., 1990; Marchler-Bauer et al., 2015). Phyre2 was used for
protein structure modelling and analysis (Kelly et al., 2015).
2.3.5. Sterol and phosphatidylinositol quantification
Fungal strains (V130-15, V130-15unc167*, and V157-62) were
grown overnight in liquid glucose minimal media in Erlenmeyer flasks
at 37 °C and 200 rpm. The fungal mass was collected via vacuum fil-
tration and dried at 60 °C for 2 h. Dried mycelia were grinded in a pestle
and mortar using liquid nitrogen, this process was repeated until a fine
powder was reached. The powder was stored in absolute ethanol until
extraction.
For ergosterol quantification, fungal samples were hydrolysed with
0.1M ethanolic KOH (Thermo Fisher Scientific, UK) containing 5α-
cholestane (Sigma Aldrich, UK) as an internal standard. Ergosterol was
extracted in hexane (Thermo Fisher Scientific, UK), dried under ni-
trogen and derivatised with MSTFA+1% TCMS (Thermo Fisher
Scientific, UK). Total (free and esterified) ergosterol concentrations
were measured by gas chromatography-mass spectrometry (GC–MS).
GC–MS analysis was performed using a Thermo Trace Ultra gas chro-
matograph fitted with a DB-5ms column (30m×0.25mm
i.d.× 0.25 µm film; Agilent J&W, USA) and coupled to a Thermo ISQ
mass spectrometer. Samples were injected (1 µl) in splitless mode using
helium as a carrier gas (1ml/min). After a delay of 2min at 150 °C, the
temperature was ramped to 300 °C at 15 °C/min and then held for
8min. The mass spectrometer was operated in selected ion monitoring
(SIM) mode using mass to charge ratio (m/z) 372 for 5α-cholestane and
m/z 468 for ergosterol.
For phosphatidylinositol quantification, extractions were performed
according to a published method (Folch et al., 1957). Phosphatidyli-
nositol 32:0 (Avanti Polar Lipids, USA) was included in the experi-
mental system as an internal standard. The samples were analysed by
liquid chromatography-mass spectrometry (LC-MS) using a Thermo
Exactive Orbitrap mass spectrometer interfaced to a Thermo Accela
1250 UHPLC system. Samples were injected (2 µl) onto a Hypersil Gold
C18 column (2.1mm×100mm, 1.9 μm; Thermo Fisher Scientific, UK)
maintained at 50 °C. Mobile phase A consisted of water containing
10mM ammonium formate and 0.1% (v/v) formic acid. Mobile phase B
consisted of 90:10 isopropanol/acetonitrile containing 10mM ammo-
nium formate and 0.1% (v/v) formic acid. The initial conditions for
analysis were 65%A/35%B. The percentage of mobile phase B was in-
creased from 35% to 65% over 4min, followed by 65%-100% over
15min held for 2min before re-equilibration to the starting conditions
over 6min. The flow rate was 400 µl/min. The mass spectrometer was
operated in negative ion mode over the mass to charge ratio (m/z)
range of 250–2000 at a resolution of 100,000. Ion signals corresponding
to the accurate m/z values for [M−H]− ions of phosphatidylinositol
34:2 (m/z 833.5186) and phosphatidylinositol 32:0 (m/z 809.5201)
were extracted from raw LC–MS data sets with the mass error set to
5 ppm.
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Ergosterol and phosphatidylinositol were measured from the same
samples and measurements were normalised to mg dry weight. Two
independent experiments were performed, comprising a total of 6
biological repeats per strain and 3 technical repeats per sample.
2.4. Ethics statement
All A. fumigatus strains used in this study were obtained from the
culture collection at the Department of Medical Microbiology, Radboud
University Medical Centre. All strains were anonymised.
2.5. Statistical analysis
All statistical analysis was performed using GraphPad Prism (ver-
sion 5). Statistical significance was assessed using a two-tailed T test; a
p value < 0.05 was considered significant.
3. Results
3.1. Reversal of G54R in cyp51A using CRISPR-Cas9
First, we wanted to establish that CRISPR-Cas9 can be used to re-
capitulate SNPs that affect antifungal drug resistance in clinical isolates
of A. fumigatus. To do this, we reversed the G54R mutation in cyp51A to
wild type (AGG→GGG) in V157-39. This mutation was then verified by
Sanger sequencing (Fig. 1A). The azole resistance phenotype of V157-
39 included itraconazole > 16mg/L, voriconazole 1mg/L and posa-
conazole > 16mg/L. Reversal of G54R to WT in cyp51A reduced
itraconazole resistance (MIC > 16–0.5mg/L) but had no effect on
posaconazole resistance (MIC > 16mg/L). Reversal of G54R did not
result in any alterations in mycelial growth rate or colony morphology.
MICs are summarised in Table 1.
3.2. Recreation of 213* in svf1
To examine the contribution of the 213* SNP in svf1 to the phenotype
of isolate V157-62, we recreated 213* (C→T) in svf1 (AFUA_5G11820),
which was identified in V157-62, in V130-15, the first isolate of the
series (verification shown in Fig. 1B). This mutation had no impact on
azole resistance but increased the susceptibility of the resultant A. fu-
migatus strain (V130-15svf1213*) to H2O2. MICs are shown in Table 1.
As shown in Fig. 2, the growth of all three strains was reduced in the
presence of 2.5mM H2O2 (e.g. p < 0.0001 for V130-15). However, the
growth of those strains that possess 213* in svf1 (V130-15svf1213* and
V157-62) was affected to a much greater extent by the presence of
2.5 mM H2O2 (p < 0.001). In comparison to when grown under
control conditions, strains V130-15svf1213* and V157-62 showed re-
ductions in 96 h colony diameters when grown with 2.5mM H2O2 of
27.5 mm and 13.2mm respectively. Interestingly, the 96 h colony dia-
meter of V130-15 with 2.5 mM H2O2 was on average only 5mm smaller
than when grown under control conditions. Therefore, the 213* SNP in
svf1 confers sensitivity H2O2.
3.3. Recreation of 167* in an uncharacterised protein
As shown in Fig. 1C, the SNP 167* (T→A) in the uncharacterised
gene AFUA_7G01960, which was identified in V157-62, was recreated
in isolate V130-15. This resulted in increased resistance to itraconazole
(MIC 1 to 4mg/L), but minimal difference to voriconazole resistance
(MIC 1 to 2mg/L). This had no effect on posaconazole or amphotericin
B susceptibility (MICs 0.25mg/L and 0.5mg/L, respectively). MICs are
displayed in Table 1.
As shown in Figs. 3 and 4, V130-15unc167* showed temperature de-
pendent differences in mycelial growth after 96 h. V130-15unc167* grew
faster than its parental strain V130-15 at room temperature (32.5 and
26.8mm, respectively (p < 0.01)). This difference became even more
pronounced at 37 °C, with a mean colony diameter of the V130-15unc167*
strain of 42.5mm and 31.3mm for the parent strain (p < 0.0001).
Growth at 42 °C showed a comparable picture, with the transformed strain
displaying a mean colony diameter 8.33mm greater than the parent V130-
15 (p < 0.01). Under all conditions tested, V157-62 had smaller mean
colony diameter in comparison to both the parent and transformant.
V130-15svf1213*
V157-39cyp51AG54R
V157-39cyp51AWT
V130-15
V130-15unc167*
V130-15
AFUA_4G06890
cyp51A
AFUA_7G01960
Uncharacterised
protein
AFUA_5G11820
svf1
A
B
C
Fig. 1. Verification of SNP generation via Sanger sequencing. (A) Verification
of A→G in cyp51A (AFUA_4G06890). (B) Verification of C→T in svf1
(AFUA_5G11820) (C). Verification of T→A in uncharacterised protein
(AFUA_7G01960).
Fig. 2. Mycelial growth of A. fumigatus strains V130-15, V130-15svf1213* and
V157-62 with or without H2O2. Solid lines indicate growth in the absence of
H2O2; dotted lines indicate growth in the presence of 2.5mM H2O2. Sabouraud
dextrose agar plates were spot inoculated with 5x102 Aspergillus conidia in 5 µl
PBS and cultured at 37 °C. Colony diameter was measured every 24 h. Data
represents two independent experiments with 3 repeats per experiment. Error
bars represent ± SD.
Fig. 3. Mycelial growth of A. fumigatus strains V130-15, V130-15unc167* and
V157-62 at different temperatures. Sabouraud dextrose agar plates were spot
inoculated with 5x102 Aspergillus conidia in 5 µl PBS and cultured at different
temperatures. Colony diameter was measured after 96 h. Data were obtained in
two experiments each comprising triplicate repeats. Mean values ± SD are
shown (*p < 0.01; ***p < 0.0001; two-tailed Students T-test).
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In order to gain insight into the possible mechanisms facilitating
these phenotypes we performed in silico analyses into this un-
characterised protein encoded by AFUA_7G01960. NCBI conserved
domain searching identified 2 conserved domains; a fungal transcrip-
tion factor middle homology region (E value= 5×10−324) and a GAL-
4-like C6 zinc binuclear cluster DNA binding domain (E
value=5.72×10−13). BLAST searching identified 138 orthologues for
the gene among 22 different Aspergillus spp; this gene shared 94.8%
identity with Aspergillus udagawae sterol uptake control protein 2 (E
value=5×10−324). Additionally, structure modelling (using Phyre2)
suggested that the AFUA_7G01960 protein shares 36% identity with the
crystal structure of sterol uptake control protein 2 (upc2) in S. cerevisiae
(p= 2×10−10) (Ha et al., 2013; Yang et al., 2015).
Overall, our in silico analyses suggested the uncharacterised gene,
AFUA_7G01960, shares similarities with genes involved in sterol reg-
ulation and encodes a putative transcription factor. This may indicate
that the generated SNP conferred the observed resistance and growth
phenotypes via alterations in membrane composition or fluidity. To
further investigate this we quantified ergosterol levels in the 3 strains.
This revealed significant differences in ergosterol content between the
strains. As shown in Fig. 5, despite variability, the parent strain (V130-
15) contained significantly more ergosterol than the mutant (V130-
15unc167*) and the strain in which the SNP was originally identified
(V157-62) (p < 0.01 and p < 0.0001 respectively).
In order to assess whether this change was associated with altera-
tions in lipid content, the phosphatidylinositol content of the strains
was also assessed. As shown in Fig. 6, phosphatidylinositol content in
V130-15 and the mutant (V130-15unc167*) were highly variable and no
significant differences were identified. However, V157-62, possessed
significantly less phosphatidylinositol in comparison to V130-15
(p < 0.05). This suggested that the SNP 167* in AFUA_7G01960 affects
ergosterol levels without significantly affecting phosphatidylinositol
levels in A. fumigatus.
Fig. 4. Morphology and growth differences of A. fumigatus strains V130-15, V130-15unc167* and V157-62 at different temperatures. Sabouraud dextrose agar plates
were spot inoculated with 5× 102 Aspergillus conidia in 5 µl PBS and cultured. Images were taken after 96 h.
Fig. 5. Quantification of total ergosterol content of A. fumigatus strain V130-15,
V130-15unc167* and V157-62. Strains were cultured overnight in liquid glucose
minimal media at 37 °C shaking at 200 rpm. Fungal mass was dried and ground
in liquid nitrogen. Samples were subjected to alkaline hydrolysis and ergosterol
was solvent extracted and derivatised. Ergosterol was then quantified using gas
chromatography-mass spectrometry (GC–MS). Data represents two independent
extraction experiments, comprising 6 biological repeats per strain and 3 tech-
nical repeats per sample. Error bars represent ± SD (*p < 0.01;
***p < 0.0001; two-tailed Students T-test).
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In order to determine whether these differences in ergosterol levels
were biologically relevant, resistance to nystatin (targeting ergosterol) and
lovastatin (targeting HMG-CoA) was assessed. Resistance to statins was
determined as a measure of metabolic activity after 48 h incubation with
nystatin or lovastatin. As shown in Fig. 7, both the mutant (V130-
15unc167*) and V157-62 showed increased resistance to 16 µg/ml nystatin
and 256 µg/ml lovastatin. In comparison to V130-15, V157-62 showed
significantly higher metabolic activity in the presence of nystatin and lo-
vastatin (p < 0.01). In comparison to the parent V130-15, V130-
15unc167* showed a significantly higher metabolic activity in the presence
of nystatin (p < 0.05), as well as in the presence of lovastatin although
this difference was not statistically significant (p=0.07). Therefore, the
observed decreases in ergosterol content correlated with increased nys-
tatin and lovastatin resistance, confirming their biological relevance.
4. Discussion
In this study, we used a CRISPR-Cas9 method to create single nu-
cleotide modifications in clinical isolates of A. fumigatus. We used this
approach to investigate the phenotypic impacts of specific SNPs that
had been acquired during the course of recurrent and chronic infection.
Firstly, we showed that a specific SNP in svf1 affects the susceptibility of
A. fumigatus to oxidative stress, inferring that svf1 contributes to oxi-
dative stress resistance. Secondly, we identified a SNP in an un-
characterised gene, AFUA_7G01960, which when recapitulated in a
wild-type strain, resulted in increased azole resistance and decreased
ergosterol content in the fungal membrane.
Investigating genetic changes using clinical strains is often chal-
lenging, as they possess wild-type akuB and therefore favour non-
homologous recombination. Excitingly, CRISPR-Cas9 technology is re-
volutionising genome editing in fungi as it overcomes the challenges of
non-homologous recombination (Ran et al., 2013). Recent publications
have shown the successful use of CRISPR-Cas9 to perform genome
editing in clinical A. fumigatus strains (Al Abdallah et al., 2017;
Umeyama et al., 2018). In this study, we first reverted the G54R mu-
tation to WT in cyp51A, to test whether the itraconazole resistance
assigned to this mutation was lost without affecting the high-level po-
saconazole resistance. This expectation was confirmed, reinforcing the
association of this mutation with itraconazole resistance but not high
level posaconazole resistance (Chen et al., 2005; Diaz-Guerra et al.,
2003; Howard et al., 2006; Mann et al., 2003; Nascimento et al., 2003;
Xu et al., 2010). No other phenotypic changes were observed, sug-
gesting minimal off target effects of CRISPR-Cas9 in A. fumigatus (Al
Abdallah et al., 2018, 2017; Umeyama et al., 2018). The resistance
mechanism conferring this high level posaconazole resistance in V157-
39 remains unknown. However, it is possible that the non-synonymous
SNPs previously identified in this isolate, influence this resistance
(Ballard et al., 2018).
Recreation of the SNP 213* in svf1 resulted in increased sensitivity
to oxidative stress. We hypothesise that this nonsense mutation causes
truncation of the protein and probably (at least partial) loss of protein
function, thereby leading to the observed oxidative stress sensitivity. In
support of our hypothesis, the orthologue of svf1 in S. cerevisiae has
been shown to be required for survival in response to oxidative stress
and mutants lacking this orthologue are unable to grow in the presence
of oxidative stress (Brace et al., 2005). The 213* SNP is particularly
interesting as it was identified in an A. fumigatus isolate infecting a
chronic granulomatous disease (CGD) patient. This patient group fails
to generate a proper phagocytic respiratory burst due to defects in ni-
cotinamide adenine dinucleotide phosphate (NADPH) oxidase, and
hence their phagocytes fail to produce high levels of reactive oxygen
species (Curnutte et al., 1974). Therefore, it is conceivable that the
oxidative stress sensitivity conferred by this SNP did not impose a
significant fitness or virulence defect in this specific host, as a proper
oxidative stress response is not mounted.
In this study we also showed that recreation of the SNP 167* in
AFUA_7G01960 increased the resistance of this strain to itraconazole,
resulted in a temperature dependent increase in growth rate, and a
significant reduction in total ergosterol content. Interestingly, da Silva
Ferreira et al., previously showed this gene to be upregulated upon
voriconazole exposure (da Silva Ferreira et al., 2006). Based on our
bioinformatics analysis, it can be hypothesised that AFUA_7G01960
encodes a putative transcription factor that promotes ergosterol
synthesis and that the introduction of this SNP attenuates the activity of
this putative transcription factor. The resulting reduction in ergosterol
levels correlated with increased resistance to lovastatin and nystatin.
Lovastatin inhibits HMG-CoA reductase, an enzyme early in the er-
gosterol biosynthetic pathway, and nystatin binds ergosterol (Harman
and Masterson, 1957; Sirtori, 1990). Therefore, the reduced levels of
ergosterol synthesis in the V130-15unc167* and V157-62 strains prob-
ably explain their enhanced statin resistance. Ergosterol is known to
regulate membrane stability and fluidity (Rodrigues, 2018). Therefore,
the alterations in ergosterol content probably impacted membrane
fluidity thereby mediating the temperature dependent effects on
growth. These alterations also have potential to confer azole resistance,
by altering membrane barrier function and as a result, intracellular
Fig. 6. Quantification of phosphatidylinositol content of A. fumigatus strain
V130-15, V130-15unc167* and V157-62. Strains were cultured overnight in li-
quid glucose minimal media at 37 °C shaking at 200 rpm. Fungal mass was dried
and ground in liquid nitrogen. Samples were subjected to chloroform-methanol
extraction. Phosphatidylinositol (32:4) was then quantified using liquid chro-
matography-mass spectrometry (LC–MS). Data represents two independent
extraction experiments, comprising 6 biological repeats per strain and 3 tech-
nical repeats per sample. Error bars represent ± SD (*p < 0.05; two-tailed
Students T-test).
Fig. 7. Susceptibility of A. fumigatus strains V130-15, V130-15unc167* and
V157-62 to lovastatin and nystatin. Metabolic activity of the strains was as-
sessed using the XTT spectrophotometric assay after 48 h incubation with
16 µg/ml nystatin and 256 µg/ml lovastatin at 37 °C. Data represents two in-
dependent experiments with 3 repeats per experiment. Error bars
represent ± SD (*p < 0.05; **p < 0.01; two-tailed Students T-test).
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accumulation of azoles (Lupetti et al., 2002).
In Candida albicans reductions in ergosterol levels have previously
been associated with increased azole resistance (Kanafani and Perfect,
2008; Kelly et al., 1997; Kohli et al., 2002; Löffler et al., 2000; Mishra
et al., 2008). In addition, a collection of fluconazole resistant clinical C.
albicans isolates were shown to possess defective sterol Δ5,6-desatura-
tion, which resulted in alteration of membrane composition to include
more 14α-methylfecosterol (Kanafani and Perfect, 2008; Kelly et al.,
1997). The putative transcription factor identified in this study showed
structural similarities to upc2 in S. cerevisiae; a G888D SNP in upc2 has
previously been reported to result in increased levels of ergosterol and
increased resistance (Ha et al., 2013; Yang et al., 2015). Recently, de-
creases in relative ergosterol levels have been associated with increased
azole resistance in A. fumigatus (Rybak et al., 2019). In our study, using
comprehensive lipidomics analysis, we were able to associate decreases
in ergosterol levels to increased azole resistance in A. fumigatus. In-
triguingly, decreases in ergosterol content did not result in higher MICs
for amphotericin B. As amphotericin B is hypothesised to target er-
gosterol this was unexpected. However, the lack of an association be-
tween decreased ergosterol content and increased amphotericin B re-
sistance, was recently also reported by others (Rybak et al., 2019). Most
likely the reduced amount of ergosterol still results in sufficient binding
of amphotericin B to the fungal cell membrane to exert its effect.
It has previously been reported that fungal cells grown in the pre-
sence of azoles contain decreased levels of ergosterol in comparison to
control conditions (Arthington-Skaggs et al., 1999; Müller et al., 2018).
We hypothesise that strain V157-62 shows an adaptation to the pre-
sence of azole antifungals in-host and is now existing in an ‘azole
adapted’ state. It is important to note that V157-62 contained lower
levels of ergosterol in comparison to V130-15unc167*, lower levels of
phosphatidylinositol in comparison to both V130-15 and V130-
15unc167* and a growth defect that was not observed in the created
mutant. It is important to note the identified SNPs do not explain the
full resistance profile of V157-62. V157-62 has an M220R SNP in
cyp51A, which does not explain the observed posaconazole or vor-
iconazole resistance (Chen et al., 2005; Garcia-Effron et al., 2005). In
addition, the identified 167* SNP in AFUA_7G01960, was shown to not
confer posaconazole or voriconazole resistance. It can be hypothesized
that a complex interplay of various SNPs confers the overall resistance
phenotype; it is of importance to unravel the contributions of individual
SNPs in order to understand the overall mechanisms. V157-62 possesses
∼29 additional non-synonymous SNPs in comparison to V130-15
(Ballard et al., 2018). It is highly likely that these SNPs are also con-
tributing to the overall resistance profile as well as the differences in
phosphatidylinositol and ergosterol levels.
5. Conclusions
In summary, clinical isolates are exposed to numerous known and
unknown stress factors, underscoring the diversity and complexity of
the adaptation process involving various pathways. Genome editing
systems such as CRISPR-Cas9 will help to gain detailed insights into the
complex interplay of SNPs involved in in-host adaptation in A. fumi-
gatus. Using CRISPR-Cas9 we have unravelled the function of specific
in-host acquired SNPs in clinical A. fumigatus isolates. We have identi-
fied a specific SNP (167* in AFUA_7G01960) that was acquired in-host
during infection and that compromises azole therapy. This SNP was
associated with non-cyp51A mediated antifungal resistance. Further
insight into the underlying mechanisms conferring resistance by this
SNP were obtained by lipidomics analysis, which showed strains pos-
sessing the SNP to have decreased ergosterol levels. As this SNP was
revealed in a clinical isolate, which acquired azole resistance in-host,
we have identified a clinically relevant novel mechanism of azole re-
sistance in A. fumigatus.
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Appendix A
See Fig. A.1 and Table A.1.
AFUA_4G06890
cyp51A
AFUA_7G01960
Uncharacterised
protein
AFUA_5G11820
svf1
GTACCATCAGTTACAGGATTGATCCCTAC
TATCCAGGGCATGAAGCCCCATCACGCT 
TCCCCGGTGATATACTCTTTGCCTTAGGA 
Fig. A.1. Schematic showing the protospacer adjacent motif (PAM), protospacer and Cas9 cut site for each target. Colour scheme is as follows: red text represents
3 bp PAM site, orange text represents 20 bp protospacer, scissors represent Cas9 cut site and underlining indicates the location of the target nucleotide for mod-
ification.
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